A Comparative Evaluation of Good Manufacturing Practices (GMP) Regulations between USFDA, WHO, and Indian Schedule M Compliance

Abstract

This study conducted a structured comparative evaluation of Good Manufacturing Practices (GMP) regulations across three influential frameworks: USFDA 21 CFR Parts 210/211, WHO GMP TRS Annexes, and India’s Schedule M. The analysis was designed around critical GMP domains—Quality Management Systems (QMS), documentation and data integrity, premises and utilities, validation, materials management, packaging and labeling, quality control, and sterile manufacturing requirements. Key findings highlight a strong common foundation across the three frameworks in areas such as documentation, cleaning validation, deviation handling, change control, QC systems, and complaint/recall mechanisms. These represent universal GMP principles that safeguard product quality and patient safety. USFDA and WHO guidance, but remain less prescriptive under Schedule M. The analysis further reveals that WHO GMP serves as a scalable international model, often used by regulators in low- and middle-income countries, while Schedule M is undergoing revisions to align with WHO/PIC/S standards. For Indian manufacturers, this dual obligation—complying with domestic Schedule M while meeting stricter USFDA/WHO expectations for exports—creates both compliance challenges and opportunities for capacity strengthening.